GSK Wins China COPD Approval for Nucala, Expanding Respiratory Biologic Footprint

GlaxoSmithKline ( (GB:GSK) ) just unveiled an announcement.

GSK has secured approval from China’s National Medical Products Administration for its biologic Nucala (mepolizumab) as an add-on maintenance treatment for adults with chronic obstructive pulmonary disease characterised by elevated blood eosinophils, making it the first and only monthly biologic in China studied in a broad COPD population with blood eosinophil counts starting at 150 cells/µL. The decision, underpinned by positive phase III MATINEE and METREX trials showing statistically significant reductions in moderate and severe exacerbations and fewer hospitalisations versus standard care, strengthens GSK’s respiratory franchise in one of the world’s largest COPD markets, where about 100 million people are affected and COPD deaths account for more than 30% of global mortality, potentially expanding Nucala’s addressable patient base beyond its existing asthma and eosinophilic indications and reinforcing the company’s competitive positioning in biologic treatments for COPD worldwide.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £17.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GB:GSK Stock

According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.

GlaxoSmithKline’s overall stock score is driven by strong financial performance and favorable valuation metrics. The company’s strategic initiatives, including share buybacks and R&D investments, support its growth outlook. However, challenges in cash flow and certain market segments warrant cautious optimism.

To see Spark’s full report on GB:GSK stock, click here.

More about GlaxoSmithKline

GSK is a global biopharma company focused on respiratory and immunology diseases, leveraging a broad portfolio of vaccines, targeted biologics and inhaled medicines. Building on decades of work in respiratory medicine, the company aims to set new standards of care for conditions such as asthma and COPD, as well as less common disorders like refractory chronic cough and systemic sclerosis with interstitial lung disease, by targeting underlying disease processes and preventing progression.

Average Trading Volume: 8,286,325

Technical Sentiment Signal: Buy

Current Market Cap: £73.89B

For detailed information about GSK stock, go to TipRanks’ Stock Analysis page.